Singota Solutions has been selected to collaborate with Noveome Biotherapeutics to manufacture the ST266 investigational drug product, a biologic being evaluated in clinical studies for its potential treatment of the severe inflammatory reaction known as Cytokine Release Syndrome (CRS), also known as the Cytokine Storm, observed in COVID-19 patients.   Singota specializes in small batch aseptic filling of high-value injectable products into vial, syringe, and cartridge formats using the robotic ...